The next generation of PDE4 inhibitors

被引：107

作者：

Huang, Z ^{[1
]}

Ducharme, Y ^{[1
]}

Macdonald, D ^{[1
]}

Robichaud, A ^{[1
]}

机构：

[1] Merck Frosst Ctr Therapeut Res, Pointe Claire, PQ H9R 4P8, Canada

来源：

CURRENT OPINION IN CHEMICAL BIOLOGY | 2001年 / 5卷 / 04期

关键词：

D O I：

10.1016/S1367-5931(00)00224-6

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

A number of highly potent PDE4 inhibitors are being developed for the treatment of asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis and Crohn's disease. Cilomilast (Ariflo(TM), SB 207499, SmithKline Beecham), the most advanced member of the class in Phase III clinical trials, was reported to have a limited therapeutic window. Other inhibitors with improved profiles in preclinical models are entering into (or are in) clinical trials. The recent developments in understanding PDE4 catalysis, inhibitor binding and their emetic response should facilitate the design of the next generation of PDE4 inhibitors.

引用

页码：432 / 438

页数：7

共 97 条

[31]

GIRARD Y, 2000, 16 INT S MED CHEM 18

[32] The cAMP-specific phosphodiesterase PDE4D3 is regulated by phosphatidic acid binding -: Consequences for cAMP signaling pathway and characterization of a phosphatidic acid binding site [J].

Grange, M ;

Sette, C ;

Cuomo, M ;

Conti, M ;

Lagarde, M ;

Prigent, AF ;

Némoz, G .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (43) :33379-33387

[33] Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis [J].

Hanifin, JM ;

Chan, SC ;

Cheng, JB ;

Tofte, SJ ;

Henderson, WR ;

Kirby, DS ;

Weiner, ES .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1996, 107 (01) :51-56

[34] Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D [J].

Hansen, G ;

Jin, SLC ;

Umetsu, DT ;

Conti, M .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (12) :6751-6756

[35]

Hatzelmann A, 2001, J PHARMACOL EXP THER, V297, P267

[36] Chronic obstructive pulmonary disease: emerging therapies [J].

Hay, DWP .

CURRENT OPINION IN CHEMICAL BIOLOGY, 2000, 4 (04) :412-419

[37] EMETIC, CENTRAL-NERVOUS-SYSTEM AND PULMONARY ACTIVITIES OF ROLIPRAM IN THE DOG [J].

HEASLIP, RJ ;

EVANS, DY .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 286 (03) :281-290

[38]

Herman SB, 2000, MOL PHARMACOL, V57, P991

[39] Palladium-catalyzed cross-coupling reactions for the synthesis of 6,8-disubstituted 1,7-naphthyridines:: A novel class of potent and selective phosphodiesterase type 4D inhibitors [J].

Hersperger, R ;

Bray-French, K ;

Mazzoni, L ;

Müller, T .

JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (04) :675-682

[40]

HOROWSKI R, 1985, CURR THER RES CLIN E, V38, P23

← 1 2 3 4 5 6 7 8 9 10 →